Proteo Biotech AG
Proteo, Inc./ Proteo Biotech AG: Phase II clinical trial with Elafin for cardiovascular disease -University of Edinburgh and Proteo sign agreement
Proteo Biotech AG / Agreement/Alliance 23.09.2009 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Irvine, CA - Kiel, 23rd September 2009 - Proteo, Inc. (OTCBB: PTEO; Frankfurter Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today the signing of a Memorandum of Understanding with the University of Edinburgh. Within the framework of a collaboration, it is intended to investigate the effect of Elafin on the damage and inflammation of cardiac muscle after coronary bypass operations in a Phase II clinical trial at the University of Edinburgh. Proteo's CEO, Birge Bargmann, views this cooperation as an excellent opportunity to expand the clinical development pipeline of the biotech company. »We are looking forward to collaborating with the University of Edinburgh and are confident that we will obtain very promising clinical results for our Lead Product, Elafin.« »We have been in contact with the Edinburgh research group for a long time and so I'm especially pleased about the clinical application of Elafin planned in patients with cardiovascular disease«, stated Professor Oliver Wiedow, Chairman of the Board of Directors of Proteo Biotech AG. »We are optimistic that Elafin will reduce cardiac muscle injury and post-operative inflammatory responses in our patients«, commented Dr. Peter Henriksen, principle investigator of the clinical trial. About Elafin Proteo's drug substance Elafin is an endogenous protein produced by the human body and is a natural inhibitor of the two tissue destroying enzymes, neutrophil elastase and proteinase-3. Both of these enzymes are known to be involved in the inflammatory response occurring in a variety of diseases. Elafin's ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or severe reperfusion injuries. The excellent tolerability of recombinant Elafin for injection in human subjects was demonstrated in a Phase I clinical trial. A Phase II clinical trial on patients undergoing esophagectomy for esophagus carcinoma has been started in the University Hospital of Schleswig-Holstein, Campus Kiel in November 2008 . The aim of the trial is to investigate the effectiveness of Elafin at suppressing the postoperative inflammatory processes. A further Phase II clinical trial has already been approved: Minapharm Pharmaceuticals SAE, Cairo, will initiate a Phase II clinical trial to study the efficacy of Elafin on kidney transplant patients. The study will be conducted as a Phase II trial for prevention of acute and chronic allograft nephropathy at the University of Cairo. About Proteo The company researches, develops and markets compounds for biological and medical research as well as for use as pharmaceuticals. The main focus is on anti-inflammatory drugs, in particular on the human elastase inhibitor Elafin. Proteo intends to out-license selected indications and to establish international strategic alliances in order to open up new fields of application and for marketing. Forward-Looking Statements Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward looking statements and risks and uncertainties involved are further qualified by other factors including, but not limited to those set forth in the company's Form 10-KSB filing and other filings with the United States Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise. Contact: Barbara Kahlke, PhD. Proteo Biotech AG Am Kiel-Kanal 44 D-24106 Kiel Email : info@proteo.de Phone: +49(0)431 8888462 Fax : +49(0)431 8888463 23.09.2009 Financial News transmitted by DGAP ---------------------------------------------------------------------------
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found